Demographic and baseline characteristics of the randomised patients
|
Tiotropium (n = 191) |
Ipratropium (n = 97) | |
| Sex (M/F) | 156/35 | 82/12 |
| Age (years) | 64 (8) | 65 (8) |
| Height (cm) | 172 (8) | 172 (7) |
| Weight (kg) | 74 (13) | 74 (12) |
| Smoking history (pack years) | 33 (16) | 35 (19) |
| Duration of disease (years) | 11 (9) | 12 (10) |
| FEV1 (l) | 1.24 (0.41) | 1.19 (0.35) |
| FEV1 (% pred) | 42 (12) | 40 (10) |
| FVC (l) | 2.84 (0.82) | 2.66 (0.74) |
| FVC (% pred) | 76 (17) | 70 (17) |
| FEV1/FVC (%) | 44 (11) | 46 (10) |
| Prestudy medication for COPD (no. (%) of patients): | ||
| Anticholinergics | 106 (56) | 53 (55) |
| β2agonists, inhaled | 137 (72) | 62 (64) |
| Steroids inhaled | 142 (74) | 78 (80) |
| Steroids oral | 17 (9) | 10 (10) |
| Theophylline | 27 (14) | 12 (12) |
Values are mean (SD). No significant differences were seen between the two groups.
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; % pred = percentage of predicted value.